Comment on esmo magnitude of clinical benefit scale

Annals of Oncology

Volumn 26, Issue 12, 2015, Pages 2504-

  Muhonen, T ^a   Joensuu, H ^a   Pfeiffer, P ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; DATA ANALYSIS; HAZARD RATIO; MAGNITUDE OF CLINICAL BENEFIT SCALE; PRIORITY JOURNAL; RATING SCALE; THERAPY EFFECT; HUMAN; NEOPLASMS; OUTCOME ASSESSMENT; PROCEDURES;

HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84949934083     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv384     Document Type: Letter

References (1)

1. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573.